ID: ALA261592

Max Phase: Preclinical

Molecular Formula: C20H20N8O

Molecular Weight: 388.44

Molecule Type: Small molecule

Representations

Synonyms (1): BMS-645737
Synonyms from Alternative Forms(1):

Canonical SMILES:  Cc1cc2cc(Nc3ncnn4cc(-c5nnc(C)o5)c(C(C)C)c34)cnc2[nH]1

Standard InChI:  InChI=1S/C20H20N8O/c1-10(2)16-15(20-27-26-12(4)29-20)8-28-17(16)19(22-9-23-28)25-14-6-13-5-11(3)24-18(13)21-7-14/h5-10H,1-4H3,(H,21,24)(H,22,23,25)

Standard InChI Key:  OOQXPATWSOGSAV-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 388.44

Molecular Weight (Monoisotopic): 388.1760

AlogP: 4.14

#Rotatable Bonds: 4

Polar Surface Area: 109.82

Molecular Species: NEUTRAL

HBA: 8

HBD: 2

#RO5 Violations: 0

HBA (Lipinski): 9

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 0

CX Acidic pKa:

CX Basic pKa: 3.46

CX LogP: 2.65

CX LogD: 2.65

Aromatic Rings: 5

Heavy Atoms: 29

QED Weighted: 0.48

Np Likeness Score: -1.32

References

1. Ruel R, Thibeault C, L'Heureux A, Martel A, Cai ZW, Wei D, Qian L, Barrish JC, Mathur A, D'Arienzo C, Hunt JT, Kamath A, Marathe P, Zhang Y, Derbin G, Wautlet B, Mortillo S, Jeyaseelan R, Henley B, Tejwani R, Bhide RS, Trainor GL, Fargnoli J, Lombardo LJ..  (2008)  Discovery and preclinical studies of 5-isopropyl-6-(5-methyl-1,3,4-oxadiazol-2-yl)-N-(2-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (BMS-645737), an in vivo active potent VEGFR-2 inhibitor.,  18  (9): [PMID:18395443] [10.1016/j.bmcl.2008.03.057]

Source

Source(1):

• Scientific Literature